Error message

  • Notice: Undefined variable: program_items in dd_program_feature_get_programs_with_keywords() (line 257 of /var/www/public/sites/all/modules/custom/dd_program_feature/dd_program_feature.module).
  • Warning: Invalid argument supplied for foreach() in dd_program_feature_get_replacements() (line 214 of /var/www/public/sites/all/modules/custom/dd_program_feature/dd_program_feature.module).
  • Notice: Undefined index: table in entity_views_plugin_row_entity_view->init() (line 20 of /var/www/public/sites/all/modules/contrib/entity/views/plugins/

About us

You are here

Management Team

Axel Mescheder, MD, CDO/CMO

Axel Mescheder was appointed Chief Development Office and Chief Medical Officer (CDO/CMO) of Lanthio in 2016. He has more than 20 years of experience in R&D management positions in the pharmaceutical and biotechnology industry. He has demonstrated the ability to successfully develop, implement and drive clinical development programs and has a track record of advancing a number of compounds through the various clinical phases that lead to product registration or label extensions, either in Europe or in the US. He joins Lanthio Pharma from Medpace GmbH, Munich/Germany, where he acted as Vice President Medical & Regulatory Affairs Europe. Prior to that, he held the positions of Chief Medical and Development Officer at TopoTarget A/S, Copenhagen/Denmark, and Medigene AG, Munich/Germany. From 2001 to 2003 he worked at MorphoSys AG as a Medical Director. Prior to that, Dr. Mescheder held various management positions in research and development at Genetics Institute/Wyeth-Ayerst Research (Pfizer), Centeon (CSL Behring) and Hoffmann-La Roche. He holds an M.D. from Christian-Albrechts-University in Kiel, Germany, specializing in pharmacology and toxicology.

Dr. Gert Moll, CSO, Managing Director

Gert combines many years of experience in research management with strong and widely published scientific expertise in the area of biological production of lanthionine-stabilized peptides. Gert did his undergraduate study in Biology at the University of Utrecht, The Netherlands, and his PhD research in the Center of Biomembranes and Lipid Enzymology at the same university in collaboration with the CNRS UA530 in Montpellier, under the direction of Prof. Dr. L.L.M. van Deenen. He subsequently worked at the INSERM U251 in Paris, France with Prof. Dr. C. le Grimellec, at the University of Padova in Italy with Prof. C. Montecucco and at the University of Groningen with Prof. Dr. W.N. Konings and Prof. Dr. A.J.M. Driessen. In this last position he focused on lanthipeptides and moved with this specialty to Biomade Technology Foundation in April 2000. He holds a chair as honorary Professor in Protein Modification and Functionality at the University of Groningen.

Christoph von Plotho,  Head of Business Administration

Christoph von Plotho brings 13 years of experience from managerial finance roles in the life science industry as well as in depth knowledge as Analyst and Investor from the buy-side to the company. He joined Lanthio Pharma as Head of Business Administration in 2017 from its parent company Morphosys where he amongst other things managed the transaction process that lead to the acquisition of Lanthio Pharma. During his 5 years at Morphosys Christoph initially reported to the CFO as Manager Special Projects setting up group-wide reporting structures and processes for budgeting and legal consolidation. In his last 3 years at Morphosys he joined the Corporate Finance Corporate Development team dealing with strategic initiatives and capital market projects as well as setting-up treasury operations. Prior to his time at MorphoSys Christoph was an Analyst and Portfolio Manager during his 4 years in New York City with Ascent Biomedical Ventures - a Venture Capital investment fund investing in private and public companies of the life science industry. In this time he managed a public equity portfolio and thereby carried out several Private Investments in Public Equity (PIPEs) in companies such as Phylogica (ASX:PYC)and Epigenomics (ETR:ECX)

Please get in touch if you would like to learn more about Lanthio Pharma.


Lanthio Pharma